Tissue Regenix Group (FRA:LSW) EBIT per Share: €-0.01 (TTM As of Jun. 2025)


FRA:LSW Tissue Regenix Group PLC FRA:LSW
10 GF Score
Price €0.07
GF Value €0.84
! 5 Warning Signs
View Full Analysis

What is Tissue Regenix Group EBIT per Share?

Tissue Regenix Group FRA:LSW 10 EBIT per Share is €-0.01 as of Jun. 2025. GuruFocus rates FRA:LSW with a GF Score™ of 10/100 and a GF Value™ of €0.84. The stock has 5 warning signs investors should review.

Tissue Regenix Group's EBIT per Share for the six months ended in Jun. 2025 was €-0.01. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2025 was €-0.01.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Tissue Regenix Group's EBIT per Share or its related term are showing as below:

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Tissue Regenix Group was 66.60% per year. The lowest was -220.80% per year. And the median was 1.30% per year.

FRA:LSW's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 15.55
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Tissue Regenix Group's EBIT for the six months ended in Jun. 2025 was €-0.42 Mil.

Tissue Regenix Group  (FRA:LSW) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Tissue Regenix Group EBIT per Share Related Terms

Tissue Regenix Group EBIT per Share Historical Data

* Premium members only.

The historical data trend for Tissue Regenix Group's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tissue Regenix Group EBIT per Share Chart

Tissue Regenix Group Annual Data
Trend Jan15 Jan16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.23 -0.06 -0.03 -0.01 0.00

Tissue Regenix Group Semi-Annual Data
Jul15 Jan16 Jul16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.01 0.00 0.00 -0.01
FRA:LSW
10GF Score
Tissue Regenix Group PLC FRA:LSW
EBIT per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tissue Regenix Group EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Tissue Regenix Group's EBIT per Share for the fiscal year that ended in Dec. 2024 is calculated as

EBIT per Share(A: Dec. 2024 )
=EBIT/Shares Outstanding (Diluted Average)
=0.304/70.994
=0.00

Tissue Regenix Group's EBIT per Share for the quarter that ended in Jun. 2025 is calculated as

EBIT per Share(Q: Jun. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-0.42/71.396
=-0.01

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of €-0.01 mean?
Tissue Regenix Group (FRA:LSW) has a EBIT per Share of €-0.01 as of Jun. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Tissue Regenix Group and its competitors.
Is Tissue Regenix Group's EBIT per Share too high?
Tissue Regenix Group's current EBIT per Share is €-0.01. Overall, Tissue Regenix Group has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Tissue Regenix Group's EBIT per Share compare to VRTX and REGN?
Tissue Regenix Group's EBIT per Share of €-0.01 can be compared against companies in the Biotechnology industry. The industry median EBIT per Share is 15.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.55, based on 1,180 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Tissue Regenix Group and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tissue Regenix Group's current EBIT per Share is €-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tissue Regenix Group stock overvalued right now?
Tissue Regenix Group (FRA:LSW) has a current EBIT per Share of €-0.01. The stock's GF Value™ is €0.84, compared to a current price of €0.07 — trading 91.7% below its estimated fair value. The current EBIT per Share is €-0.01. Tissue Regenix Group's overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Tissue Regenix Group (FRA:LSW), the current EBIT per Share is €-0.01 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tissue Regenix Group (FRA:LSW) Overvalued in 2026?

Based on GuruFocus' analysis, Tissue Regenix Group stock appears to be undervalued. The current stock price of €0.07 is trading 91.7% below its estimated GF Value™ of €0.84.

Key valuation signals for FRA:LSW:

  • EBIT per Share: €-0.01
  • GF Value™: €0.84 vs. price of €0.07 (91.7% below fair value)
  • GF Score™: 10/100 with 5 warning signs

No single metric tells the full story. See the FRA:LSW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tissue Regenix Group Business Description

Address Lotherton Way, Unit 3, Phoenix Court, Garforth, GBR, LS25 2GY
Tissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Its product portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States.
10GF Score

Get the complete analysis for FRA:LSW

EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.07
Price
€0.84
GF Value